[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bile-duct-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bile-duct-carcinoma":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,61,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":42,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100571099","target-specific-immunopet-imaging-of-digestive-system-carcinoma-100571099",false,"NCT06715839","Target-specific immunoPET Imaging of Digestive System Carcinoma","Development and Clinical Translation of immunoPET Imaging Probes for Digestive System Carcinoma","Inclusion Criteria:\n\n1. Aged 18-75 years old and of either sex；\n2. Histologically confirmed diagnosis of digestive system carcinoma or suspected digestive system carcinoma by diagnostic imaging;\n3. Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n1. Pregnancy；\n2. Severe hepatic and renal insufficiency;\n3. History of serious surgery in the last month;\n4. Allergic to antibody or single-domain antibody radiopharmaceuticals.","ALL","18 Years","75 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of this study is to establish and optimize the target-specific PET\u002FCT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in digestive system malignant tumors will be evaluated.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41],"Malignancy","Digestive Cancer","Digestive System Neoplasm","Digestive System Carcinoma","Digestive System Cancer","Liver Cancer","Stomach Cancer","Colon Cancer","Rectum Cancer","Pancreatic Cancer","Esophagus Cancer","Gallbladder Carcinoma","Small Intestine Cancer","Appendix Cancer","Bile Duct Carcinoma",[43,44,45,46,47],"human epidermal growth factor receptor 2 (HER2)","Trophoblast cell surface antigen 2 (TROP2)","Glypican-3 (GPC3)","Glycoprotein A33 (gpA33)","Nectin cell adhesion molecule-4 (Nectin-4)","RECRUITING","2025-12-25",{"date":51,"type":52},"2025-12-31","ACTUAL",{"date":54,"type":52},"2024-12-04",{"date":56,"type":21},"2027-09",{"name":58,"class":59},"RenJi Hospital","OTHER",1,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":71,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":60},"100602191","phase-4-study-of-large-channel-digital-pancreaticobiliary-scope-dps-with-compatible-accessories-100602191","NCT07120295","Study of Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories","Prospective Multicenter Clinical Performance Study of a Single-use Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories","Inclusion Criteria:\n\n1. Provision to sign and date the consent form;\n2. Adult patients ≥ 21 years old;\n3. Any patient who is required to undergo endoscopic retrograde cholangiopancreatography (ERCP) procedure with the clinical need to perform cholangioscopy for:\n\n   1. Indeterminate biliary stricture, or\n   2. Failed biliary stone extraction with conventional techniques.\n4. Willing and able to follow study procedures and comply with study follow-up.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation;\n2. Surgically or physiologically altered GI anatomy that precludes advancement of the duodenoscope for biliary cannulation;\n3. Patients on anti-coagulants and anti-platelet medications that cannot be withheld pre-procedure, except for aspirin, 81mg;\n4. Coagulopathy (INR \\> 1.8) or thrombocytopenia (Platelets \\\u003C 50,000) that is not correctable and felt to be a contraindication to proceeding with biopsy or lithotripsy per the treating endoscopist;\n5. Active suppurative cholangitis with evidence of purulent drainage at the time of papilla visualization;\n6. Patients who are not candidates for anesthesia to permit ERCP.","21 Years",{"count":70,"type":21},75,[72],"PHASE4","This study plans to enroll up to 75 research subject who have a biliary disorder such as bile duct stones or intermediate biliary strictures. The purpose of this research is to assess whether the Dragonfly™ Pancreaticobiliary Scope functioned as intended in combination with the commercially available accessories during your scheduled endoscopy procedure. This includes achieving stone fragmentation of difficult biliary stone(s) while obtaining adequate tissue specimens for analysis. There will also be a Product performance evaluation as rated by the endoscopist operating the DPS System and evaluation of ergonomics and usability.",[75,41],"Bile Duct Adenocarcinoma","2025-08-28",{"date":78,"type":52},"2025-09-05",{"date":80,"type":52},"2025-08-11",{"date":82,"type":21},"2028-12",{"name":84,"class":59},"University of Colorado, Denver",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":97,"conditions":98,"keywords":102,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":60},"100594878","phase-2-sequential-anti-angiogenic-therapy-after-immunotherapy-in-advanced-biliary-tract-cancer-100594878","NCT07025174","Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer","Evaluation of the Effect of Sequential Anti-angiogenic Therapy Following Immune Therapy Progression on Survival in Patients With Advanced Biliary Tract Malignancies: A Randomized, Multi-center, Exploratory Clinical Study","SAIB","Inclusion Criteria:\n\nAge 18-75 years at time of enrollment; Histologically or cytologically confirmed advanced or metastatic biliary tract adenocarcinoma (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder carcinoma); Unresectable locally advanced or metastatic disease not amenable to curative treatment; At least one measurable lesion according to RECIST version 1.1 criteria; ECOG Performance Status 0-1; Life expectancy ≥ 12 weeks; No prior systemic chemotherapy, immunotherapy, or anti-angiogenic therapy for advanced disease (adjuvant therapy completed \\>6 months prior is allowed); Adequate bone marrow function: ANC ≥1.5×10⁹\u002FL, platelets ≥100×10⁹\u002FL, hemoglobin ≥90 g\u002FL; Adequate liver function: Total bilirubin ≤2.5×ULN, ALT and AST ≤3×ULN (or ≤5×ULN if liver metastases present); Adequate renal function: Serum creatinine ≤1.5×ULN or creatinine clearance ≥50 mL\u002Fmin; Signed informed consent.\n\nExclusion Criteria:\n\nMixed histology tumors or neuroendocrine components; Active central nervous system metastases (treated and stable metastases \\>4 weeks allowed); History of other malignancies within 5 years (except adequately treated basal cell carcinoma, squamous cell carcinoma of skin, or carcinoma in situ); Active autoimmune disease requiring systemic treatment; History of severe allergic reactions to monoclonal antibodies or study drug components; Uncontrolled hypertension (\\>140\u002F90 mmHg despite medication); Significant cardiovascular disease including unstable angina, myocardial infarction within 6 months, or NYHA Class III-IV heart failure; Active bleeding or bleeding tendency, thrombosis, or use of anticoagulants; Major surgery within 4 weeks or minor surgery within 2 weeks; Active infection requiring systemic treatment; Pregnancy or breastfeeding; HIV infection, active hepatitis B or C infection; Psychiatric illness that would limit compliance with study requirements.",{"count":94,"type":21},60,[96],"PHASE2","Brief Summary:\n\nThis study is for patients with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The purpose is to find out if using anti-blood vessel formation drugs after immunotherapy treatment can help patients live longer without their cancer getting worse.\n\nWhat the study compares:\n\nControl group: Patients receive standard chemotherapy as first-line treatment, then chemotherapy plus anlotinib (an anti-blood vessel drug) if their cancer progresses Treatment group: Patients receive chemotherapy plus immunotherapy as first-line treatment, then the same second-line treatment as the control group if their cancer progresses\n\nWho can join:\n\nPatients aged 18-75 with advanced biliary tract cancer that has been confirmed by tissue testing, who have not received immunotherapy or anti-blood vessel drugs before, and who are in good enough health for treatment.\n\nWhat we want to learn:\n\nThe main goal is to see if patients who received immunotherapy first have better outcomes when they later receive anti-blood vessel treatment. We will measure how long patients live without their cancer getting worse during second-line treatment.\n\nStudy design:\n\nThis is a randomized study, meaning patients are assigned by chance to one of the two treatment groups. About 60 patients will participate across multiple hospitals in China. We will also collect blood and tissue samples to better understand how these treatments work.\n\nThe study will help doctors determine if this treatment sequence could become a new standard approach for patients with advanced biliary tract cancer.",[41,99,100,101],"Gall Bladder Cancer","Biliary Tract Cancer","Cholangiocarcinoma",[103,104,105,106,107],"Biliary tract cancer","Immunotherapy","Anti-angiogenic therapy","Anlotinib","Sequential therapy","2025-06-10",{"date":110,"type":52},"2025-06-17",{"date":112,"type":52},"2025-06-01",{"date":114,"type":21},"2027-12-31",{"name":116,"class":59},"First Affiliated Hospital of Zhejiang University"]